Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and Rituximab in Severe Systemic Lupus Erythematosus
NCT03747159Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2018
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belimumab and rituximab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Treatment failure rate at 2 years. Started Oct 2018; status: completed.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03747159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747159.